Rakuten Investment Management Inc. Makes New Investment in Cencora, Inc. $COR

Rakuten Investment Management Inc. purchased a new stake in Cencora, Inc. (NYSE:COR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 55,442 shares of the company’s stock, valued at approximately $17,327,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Cencora during the second quarter worth $695,215,000. Mizuho Markets Americas LLC grew its position in Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after acquiring an additional 1,511,906 shares during the last quarter. Artisan Partners Limited Partnership acquired a new position in Cencora in the 2nd quarter worth about $411,888,000. Vanguard Group Inc. raised its position in Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the last quarter. Finally, Viking Global Investors LP boosted its stake in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Mizuho lifted their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Barclays started coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, Wells Fargo & Company lifted their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $381.42.

Cencora Stock Performance

Shares of COR opened at $350.72 on Wednesday. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The firm’s fifty day simple moving average is $349.16 and its two-hundred day simple moving average is $321.12. Cencora, Inc. has a 12 month low of $237.71 and a 12 month high of $377.54. The stock has a market capitalization of $68.04 billion, a P/E ratio of 44.12, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the company posted $3.34 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,220 shares of company stock valued at $5,343,561 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.